NorthWest Biotherapeutics Inc (NWBO)

[Magrit]

Dr. Liau’s lecture at 13:38 was discussing development of future trial designs and treatment decisions by their cancer markers. My understanding is these types of immunotherapy trials didn’t differentiate between mgmt methylated and unmethylated gbm. My impression was she was talking about historical immunotherapy trials that included a now known population that doesn’t respond well to immunotherapy. For me she was implying the 20-25% result was due to this population’s inclusion in the trial and obscuring the statistical significance of the trial for the group that responds well to immunotherapy.